Bachem to expand in asian markets
Subsidiary in Tokyo founded
Bachem announces the establishment of Bachem Japan K.K., a subsidiary in Tokyo, Japan. This new local presence in Asia will strengthen project and customer support and drive further business growth in the Asian market.
"This is an exciting step for Bachem", comments Dr. Anne-Kathrin Stoller, Chief Marketing Officer of Bachem Holding AG. "The Asian market and Japan in particular have become increasingly important for Bachem. Therefore, we decided to establish a third regional pillar alongside Europe and North America. Bachem Japan K.K. assumes sales responsibility for our Active Pharmaceutical Ingredients (API) business in Japan and other Asian countries such as South Korea, China and Taiwan. This will enable us to serve our customers even more effectively and further expand our Asian business together with existing and future partners".
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease
NiKem Research and Chiesi Farmaceutici Extend Research Collaboration
Oxford BioMedica and EntreMed enter agreement on RetinoStat(TM) programme

OrganoTherapeutics SARL - Esch-sur-Alzette, Luxembourg
Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration - Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies

Small-volume, high-throughput organic synthesis - New method synthesizes and evaluates large number of drug leads
